Clinical Trials Logo

Advanced Malignant Solid Tumors clinical trials

View clinical trials related to Advanced Malignant Solid Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04328506 Completed - Clinical trials for Advanced Malignant Solid Tumors

Bioequivalency Study of CM082 Tablet in Healthy Volunteers

Start date: June 1, 2020
Phase: Phase 1
Study type: Interventional

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.

NCT ID: NCT04126668 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers

Start date: December 19, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.

NCT ID: NCT01128842 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.

NCT ID: NCT00958724 Completed - Clinical trials for Advanced Malignant Solid Tumors

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.

NCT ID: NCT00884845 Completed - Clinical trials for Advanced Malignant Solid Tumors

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Start date: January 2009
Phase: Phase 1
Study type: Interventional

Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.

NCT ID: NCT00768469 Completed - Clinical trials for Advanced Malignant Solid Tumors

Study Evaluating Safety And Tolerability, Solid Tumor

Start date: October 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

NCT ID: NCT00728468 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Start date: September 2008
Phase: Phase 1
Study type: Interventional

Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.

NCT ID: NCT00706030 Completed - Breast Cancer Clinical Trials

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Start date: April 29, 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of HKI-272 and vinorelbine in patients with advanced solid tumors. In the second part of the study, approximately 60 additional subjects with metastatic ErbB-2-positive breast cancer, with no prior exposure to lapatinib, are planned to be added to better define the tolerability and preliminary activity of HKI-272 in combination with vinorelbine. Up to 20 additional subjects with ErbB-2-positive breast cancer with prior lapatinib exposure are also planned to be enrolled in part 2 for exploratory analyses.

NCT ID: NCT00445458 Completed - Breast Neoplasms Clinical Trials

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Start date: September 11, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.